Form 4 for ANIP ANI PHARMACEUTICALS INC
Accepted 2022-03-23 00:00:00 ET · period of report 2022-03-21 · accession 0001415889-22-003308 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-03-23 | 2022-03-21 | ANIP | Lalwani Nikhil | Pres, CEO, Dir | P - Purchase | $27.69 | +7,224 | 169.7K | +4% | +$200.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-21 | P | A | 7,224 | $27.69 | 169,650 | D | — | — | (F1) The shares were acquired in multiple trades at prices ranging from $26.885 to $27.8058. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. |